Observational studyRheumatology international2024

Tocilizumab plus Nintedanib for progressive interstitial lung disease in systemic sclerosis: a one-year observational study.

Stylianos Panopoulos et al.PubMed ↗Publisher ↗

No numbers read from the abstract.